Risk of depression dims hopes for anti-addiction pills
<p><a href="http://us.rd.yahoo.com/dailynews/rss/health/*http://news.yahoo.com/s/ap/20080423/ap_on_he_me/super_pills"><img src="http://d.yimg.com/us.yimg.com/p/ap/20080423/capt.88cc36cf9684425aa02e8588fdf1bf7b.super_pills_ny451.jpg?x=130&y=86&q=85&sig=RNrWftMa2ztsNkVJrfxPfg--" align="left" height="86" width="130" alt="Margaret Bastian poses for a photo in Fairport, N.Y., Friday, April 18, 2008. Bastian had problems with the drug Chantix, the highly touted quit-smoking pill that targets a different pleasure pathway, which has also been linked to dozens of suicides and hundreds of suicidal behaviors. The Pfizer Inc. drug went on sale in August 2006 in the U.S. and is sold as Champix in other countries. (AP Photo/David Duprey)" border="0" /></a>AP - Two years ago, scientists had high hopes for new pills that would help people quit smoking, lose weight and maybe kick other tough addictions like alcohol and cocaine.</p><br clear="all"/>

Read more...